Christina Lamers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christina Lamers has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Alexander John Lander
University of Basel
1 shared publication Carla Johanna Sommer-Plüss
Molecular Pharmacy Research Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
1 shared publicationDaniel Ricklin
Molecular Pharmacy Research Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
1 shared publication- Daniel Ricklin
Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
1 shared publication - Ekaterina S. Umnyakova
Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
1 shared publication - John D. Lambris
University of Pennsylvania
1 shared publication
Latest Publications
- Open Access
Phage Display-Derived Cyclic Peptides as Ligand-Specific Modulators for β 2 -Integrin Receptors
The leukocyte-specific β 2 -integrin receptor family exerts a wide range of functions: β 2 -integrins are involved in leukocyte trafficking, where they mediate cell adhesion during inflammatory responses via binding to ICAM-1, ICAM-2, or JAM-C. Furthermore, they are essential for the recognition and phagocytosis of pathogens opsonized by complement. Accordingly, the β 2 -integrin family is known to be involved in autoimmune and inflammatory diseases, such as systemic lupus erythematosus. Owing to their complex biology, involving multiple conformational transitions, different signaling pathways, and a broad spectrum of ligands, the development of β 2 -integrin-targeted probes and therapeutics has remained challenging. We aimed to develop macrocyclic peptides, derived from phage display screening, which can be used to unravel ligand binding profiles of β 2 -integrins with an emphasis on the αI domain. The selection of suitable lead peptides, and the characterization of their interaction profiles with different αI domains, was enabled by an established in-vitro assay platform. Various peptide sequences were enriched during several rounds of phage display against the αI-domain of CR3, of which two peptides with particularly low micromolar binding affinity were further characterized. Both peptides showed direct binding to β 2 -integrin αI-domains and, in a competitive assay, dose-dependent inhibition of the αI-domains’ interactions with their main ligands iC3b and ICAM-1, respectively. These ligand-interfering properties were confirmed in bead- and cell-based adhesion assays. The modulators developed here are expected to provide valuable insight into the (patho-)physiology of CR3 and the other members of the β 2 -integrin family, as the two peptides were able to compete with different ligands. In the future, this may help to identify potential therapeutic approaches for autoimmune, inflammatory, and age-related diseases.
Open AccessPhage Display-Derived Cyclic Peptides as Ligand-Specific Modulators for β 2 -Integrin Receptors
The leukocyte-specific β 2 -integrin receptor family exerts a wide range of functions: β 2 -integrins are involved in leukocyte trafficking, where they mediate cell adhesion during inflammatory responses via binding to ICAM-1, ICAM-2, or JAM-C. Furthermore, they are essential for the recognition and phagocytosis of pathogens opsonized by complement. Accordingly, the β 2 -integrin family is known to be involved in autoimmune and inflammatory diseases, such as systemic lupus erythematosus. Owing to their complex biology, involving multiple conformational transitions, different signaling pathways, and a broad spectrum of ligands, the development of β 2 -integrin-targeted probes and therapeutics has remained challenging. We aimed to develop macrocyclic peptides, derived from phage display screening, which can be used to unravel ligand binding profiles of β 2 -integrins with an emphasis on the αI domain. The selection of suitable lead peptides, and the characterization of their interaction profiles with different αI domains, was enabled by an established in-vitro assay platform. Various peptide sequences were enriched during several rounds of phage display against the αI-domain of CR3, of which two peptides with particularly low micromolar binding affinity were further characterized. Both peptides showed direct binding to β 2 -integrin αI-domains and, in a competitive assay, dose-dependent inhibition of the αI-domains’ interactions with their main ligands iC3b and ICAM-1, respectively. These ligand-interfering properties were confirmed in bead- and cell-based adhesion assays. The modulators developed here are expected to provide valuable insight into the (patho-)physiology of CR3 and the other members of the β 2 -integrin family, as the two peptides were able to compete with different ligands. In the future, this may help to identify potential therapeutic approaches for autoimmune, inflammatory, and age-related diseases.
- Open Access
- 4 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
New analogs of the compstatin family of clinical complement inhibitors with low picomolar target affinity
Macrocyclic peptides of the compstatin family have emerged as therapeutic complement system modulators. Alongside an approved PEGylated derivative, sequence-optimized compstatin analogs with enhanced PK/PD properties have shown clinical promise. By extending the structure-activity relationship of compstatin, we characterized a highly beneficial V3I modification that enhances compstatin’s target affinity up to 30-fold and show that the additional gamma-methyl group addresses a specific target pocket. Novel analog Cp01-V3I represents the most potent analog comprised entirely of canonical amino acids (KD = 20 nM), opening a path toward recombinant applications. Meanwhile, the V3I modification can be transferred to late-generation analogs to obtain a low-picomolar-affinity derivative (KD = 0.08 nM), termed Cp60, with potent complement inhibition in vitro. Lastly, we demonstrate that Cp60’s ultra-long target residence enables new applications as a diagnostic tool for the detection of complement opsonins on biosurfaces. Collectively, this work highlights the importance of vigorous optimization of de novo peptide inhibitors to improve PK/PD properties and enable novel applications.
- 4 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessNew analogs of the compstatin family of clinical complement inhibitors with low picomolar target affinity
Macrocyclic peptides of the compstatin family have emerged as therapeutic complement system modulators. Alongside an approved PEGylated derivative, sequence-optimized compstatin analogs with enhanced PK/PD properties have shown clinical promise. By extending the structure-activity relationship of compstatin, we characterized a highly beneficial V3I modification that enhances compstatin’s target affinity up to 30-fold and show that the additional gamma-methyl group addresses a specific target pocket. Novel analog Cp01-V3I represents the most potent analog comprised entirely of canonical amino acids (KD = 20 nM), opening a path toward recombinant applications. Meanwhile, the V3I modification can be transferred to late-generation analogs to obtain a low-picomolar-affinity derivative (KD = 0.08 nM), termed Cp60, with potent complement inhibition in vitro. Lastly, we demonstrate that Cp60’s ultra-long target residence enables new applications as a diagnostic tool for the detection of complement opsonins on biosurfaces. Collectively, this work highlights the importance of vigorous optimization of de novo peptide inhibitors to improve PK/PD properties and enable novel applications.